LEMD3

Across TCGA pan-cancer cohorts, LEMD3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LEMD3 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LEMD3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LEMD3 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where LEMD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.247	0.574	.001	26	view →
GBM	DFS	Quartile	All	0.833	0.606	.003	19	view →
HNSC	DFS	Median	III,IV	0.903	1.000	.004	12	view →
CCRCC	DFS	Median	IV	0.220	0.781	.017	10	view →
LUAD	DFS	Tertile	All	0.836	1.000	.022	5	view →
LSCC	DFS	Quartile	All	1.000	0.946	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LEMD3–PDAC (DFS)

Open the PDAC breakdown →